Papillomavirus

BioVaxys Broadens Intellectual Property Portfolio Commercial Trademark Application Filed for CoviDTH® Diagnostic

Retrieved on: 
Thursday, April 29, 2021

CoviDTH is an ideal mark as it combines the letters DTH, or delayed type hypersensitivity, the mechanism behind our T-cell immune response diagnostic, with Covid-19.

Key Points: 
  • CoviDTH is an ideal mark as it combines the letters DTH, or delayed type hypersensitivity, the mechanism behind our T-cell immune response diagnostic, with Covid-19.
  • "\nIn another action that further builds their IP portfolio, BioVaxys broadened the patent coverage for its bihaptenized tumor antigen vaccine platform by filing an international patent application through the Patent Cooperation Treaty ("PCT") with additional claims for cervical cancer.
  • is a British Columbia-registered, early stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics.
  • BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.

BioVaxys Broadens Intellectual Property Portfolio Commercial Trademark Application Filed for CoviDTH® Diagnostic

Retrieved on: 
Thursday, April 29, 2021

CoviDTH is an ideal mark as it combines the letters DTH, or delayed type hypersensitivity, the mechanism behind our T-cell immune response diagnostic, with Covid-19.

Key Points: 
  • CoviDTH is an ideal mark as it combines the letters DTH, or delayed type hypersensitivity, the mechanism behind our T-cell immune response diagnostic, with Covid-19.
  • "\nIn another action that further builds their IP portfolio, BioVaxys broadened the patent coverage for its bihaptenized tumor antigen vaccine platform by filing an international patent application through the Patent Cooperation Treaty ("PCT") with additional claims for cervical cancer.
  • is a British Columbia-registered, early stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics.
  • BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.

Agenus Submits Balstilimab Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer

Retrieved on: 
Monday, April 19, 2021

These clinical data, along with preclinical data, suggest that balstilimab demonstrates differentiated features from other anti-PD-1 antibodies.\n\xe2\x80\x9cWomen with recurrent or metastatic cervical cancer have a very poor prognosis and limited treatment options.

Key Points: 
  • These clinical data, along with preclinical data, suggest that balstilimab demonstrates differentiated features from other anti-PD-1 antibodies.\n\xe2\x80\x9cWomen with recurrent or metastatic cervical cancer have a very poor prognosis and limited treatment options.
  • Data suggest balstilimab may bring benefit to patients beyond what is available in this disease setting today,\xe2\x80\x9d said Jennifer Buell, PhD, President and Chief Operating Officer at Agenus.
  • Cervical cancer remains one of the leading causes of cancer death in women globally, annually killing more than 300,000 women worldwide.1 Despite advances in routine medical examinations and HPV vaccines, cervical cancer remains prevalent.
  • When left undetected, recurrent or metastatic cervical cancer often develops, for which there are limited treatment options and a low chance of survival.

Antiva Biosciences Appoints Clifford Samuel to Board of Directors

Retrieved on: 
Wednesday, April 21, 2021

b'SOUTH SAN FRANCISCO, Calif., April 21, 2021 /PRNewswire/ --Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, today announced the appointment of Clifford Samuel to the company\'s board of directors.

Key Points: 
  • b'SOUTH SAN FRANCISCO, Calif., April 21, 2021 /PRNewswire/ --Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, today announced the appointment of Clifford Samuel to the company\'s board of directors.
  • Mr. Samuel\'s deep passion for global health and his commitment to universal patient access to novel therapies are well-aligned with our mission.
  • "\nMost recently Mr. Samuel served as the Senior Vice President, Global Patient Solutions at Gilead, which included responsibility for more than 140 countries.
  • I\'m excited to join the Antiva board and help their team to maximize the global reach of their product.

BioVaxys Announces Final Clinical trial results of HPV product from EU partner ProCare Health Iberia published by American Society for Colposcopy and Cervical Pathology

Retrieved on: 
Wednesday, April 14, 2021

"The results of the Paloma trial are really good news for HPV patients thanks to the proven efficacy of Papilocare.

Key Points: 
  • "The results of the Paloma trial are really good news for HPV patients thanks to the proven efficacy of Papilocare.
  • is a British Columbia-registered, early stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics.
  • BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.
  • BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trades on the Frankfurt Bourse (FRA: 5LB) and US OTC: LMNGF.\n'

BioVaxys Announces Final Clinical trial results of HPV product from EU partner ProCare Health Iberia published by American Society for Colposcopy and Cervical Pathology

Retrieved on: 
Wednesday, April 14, 2021

"The results of the Paloma trial are really good news for HPV patients thanks to the proven efficacy of Papilocare.

Key Points: 
  • "The results of the Paloma trial are really good news for HPV patients thanks to the proven efficacy of Papilocare.
  • is a British Columbia-registered, early stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics.
  • BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.
  • BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trades on the Frankfurt Bourse (FRA: 5LB) and US OTC: LMNGF.\n'

Precigen Receives FDA Orphan Drug Designation for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)

Retrieved on: 
Thursday, March 18, 2021

In January 2021, Precigen announced the clearance of the IND to Initiate a Phase I study of PRGN-2012 AdenoVerse immunotherapy in adult patients with RRP (clinical trial identifier: NCT04724980 ).

Key Points: 
  • In January 2021, Precigen announced the clearance of the IND to Initiate a Phase I study of PRGN-2012 AdenoVerse immunotherapy in adult patients with RRP (clinical trial identifier: NCT04724980 ).
  • Orphan drug designation is granted by the FDA to drugs intended to treat rare diseases or disorders that affect fewer than 200,000 people in the US.
  • "As the first regulatory designation for our proprietary AdenoVerse platform, this orphan drug designation will help to advance PRGN-2012 with important incentives that support delivery of this medicine as rapidly as possible to patients suffering from RRP."
  • "Human papillomavirus infection in papillomas and nondiseased respiratory sites of patients with recurrent respiratory papillomatosis using the polymerase chain reaction."

Vaccitech Doses First Patient in HPV001, a Phase 1/2 Clinical Trial of VTP-200 Immunotherapeutic for High-risk Persistent HPV Infection

Retrieved on: 
Thursday, March 18, 2021

HPV001 is a randomized, placebo-controlled Phase 1/2 clinical trial designed to evaluate the safety and preliminary efficacy of VTP-200, Vaccitechs immunotherapy for high-risk HPV infection and associated low-grade cervical intraepithelial neoplasia.

Key Points: 
  • HPV001 is a randomized, placebo-controlled Phase 1/2 clinical trial designed to evaluate the safety and preliminary efficacy of VTP-200, Vaccitechs immunotherapy for high-risk HPV infection and associated low-grade cervical intraepithelial neoplasia.
  • VTP-200 targets six early proteins from five different high-risk HPV groups and therefore covers more types of HPV than any other immunotherapy previously tested.
  • Nearly all global cases of cervical cancer are caused by HPV, said Bill Enright, Chief Executive Officer of Vaccitech.
  • A non-invasive solution to clear HPV infection and the spectrum of diseases it causes is urgently needed.

Global Cervical Cancer Diagnostic Tests Market to Surpass US$ 9,010.4 Million by 2027, Says Coherent Market Insights (CMI)

Retrieved on: 
Friday, March 12, 2021

According to Coherent Market Insights, the global cervical cancer diagnostic tests market is estimated to be valued at US$ 5,910.2 million in 2020 and is expected to exhibit a CAGR of 6.2% over the forecast period (2020-2027).

Key Points: 
  • According to Coherent Market Insights, the global cervical cancer diagnostic tests market is estimated to be valued at US$ 5,910.2 million in 2020 and is expected to exhibit a CAGR of 6.2% over the forecast period (2020-2027).
  • Furthermore, key players operating in the global cervical cancer diagnostic tests market are focusing on adoption of inorganic growth strategies such as acquisition and collaboration in order to increase their market presence in the global market.
  • The global cervical cancer diagnostic tests market is expected to exhibit a CAGR of 6.2% over the forecast period, owing to increasing incidence of cervical cancer.
  • Global Cervical Cancer Diagnostic Tests Market, By Test Type:

Transgene Expands Phase II Clinical Trial of Therapeutic Vaccine TG4001 in Combination With Avelumab Versus Avelumab Monotherapy in Patients With HPV16-positive Anogenital Cancers

Retrieved on: 
Wednesday, March 10, 2021

Transgene has amended the initial Phase Ib/II trial protocol to enable a more rapid start of this important Phase II study based on encouraging Phase Ib/II trial data.

Key Points: 
  • Transgene has amended the initial Phase Ib/II trial protocol to enable a more rapid start of this important Phase II study based on encouraging Phase Ib/II trial data.
  • The initial Phase Ib/II trial conducted in Europe (France and Spain) has been amended to include a randomized comparison of the combination of TG4001 with avelumab versus avelumab monotherapy in anogenital cancers.
  • Patients will be randomized to either receive the combination regimen of the therapeutic vaccine TG4001 and avelumab or avelumab alone.
  • The combination of TG4001 and avelumab demonstrated anti-tumor activity (23.5% ORR) in patients with previously treated recurrent and/or metastatic HPV-related cancers (including patients with oropharyngeal cancers and anogenital cancers).